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Abstract
Background: Genetic testing is increasingly used as a tool throughout the health care system. In 2011 the number
of clinically available genetic tests is approaching 2,000, and wide variation exists between these tests in their
sensitivity, specificity, and clinical implications, as well as the potential for discrimination based on the results.
Discussion: As health care systems increasingly implement electronic medical record systems (EMRs) they must
carefully consider how to use information from this wide spectrum of genetic tests, with whom to share
information, and how to provide decision support for clinicians to properly interpret the information. Although
some characteristics of genetic tests overlap with other medical test results, there are reasons to make genetic test
results widely available to health care providers and counterbalancing reasons to restrict access to these test results
to honor patient preferences, and avoid distracting or confusing clinicians with irrelevant but complex information.
Electronic medical records can facilitate and provide reasonable restrictions on access to genetic test results and
deliver education and decision support tools to guide appropriate interpretation and use.
Summary: This paper will serve to review some of the key characteristics of genetic tests as they relate to design
of access control and decision support of genetic test information in the EMR, emphasizing the clear need for
health information technology (HIT) to be part of optimal implementation of genetic medicine, and the
importance of understanding key characteristics of genetic tests when designing HIT applications.
Keywords: genetic tests, electronic medical records, privacy, storage of genetic information, access to genetic
information, types of genetic information
Background
A strength of electronic medical record (EMR) systems is
that they not only provide a mechanism to store and
organize patient health information but also provide the
ability to filter health information based on clinical utility
or relevance to individual clinical specialties, provide
education and clinical decision support, and implement
patient preferences around access to health information.
For example, design of EMR interfaces requires decisions
regarding what to present when to clinicians, as user
interface design determines what information clinicians
will access and notice when delivering clinical care.
G e n e t i cm e d i c i n ei sa na r e ai nw h i c ht h e s es t r e n g t h so f
EMRs are of particular importance for ensuring efficient,
effective, and ethical use of what can often be complex
and sensitive findings. In this manuscript we explore key
factors to consider in EMR design decisions regarding
access controls on genetic testing results, and discuss
characteristics of classes of genetic tests relevant to how
EMRs use, display, and offer decision support for genetic
testing information.
Genetic testing is an increasingly common tool used
throughout health care, but little has been done to opti-
mize use of genetic information in EMRs. The number of
clinically available tests is rapidly increasing, and health-
care professionals are using them on a more regular
basis. At the time of this writing, tests for almost 2,000
clinical conditions exist [1]. For example, genetic tests on
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intellectual disabilities are now typically used to establish
a diagnosis, which in turn can assist in determining prog-
nosis, finding the most effective treatments, and making
other health care decisions. Many patients with earlier
than typical cancers (before age 50) or with extensive
family histories of cancer [2] are now referred for genetic
testing to help determine the most appropriate screening
and prevention therapies. Genetic testing may also detect
the existence of treatable metabolic disorders. These are
only three examples of the current clinical uses of genetic
testing. However, a recent study [3] reported that most
surveyed health care professionals reported that EMRs
had poor systems for online test ordering, little decision
support for genetic test ordering, and treated the genetic
test results similarly to other medical test results [3].
While genetic information has similarities to non-
genetic personal health information there are some key
differences, well-outlined in McGuire et al [4]. These
distinctive properties include the uniqueness of genetic
information, leading to identifiability of an individual; the
predictive capability of genetic test results; the perma-
nence of genetic changes; the impact on family members;
the temporality of the data interpretation; and the history
of eugenics [4]. As with many other medical tests, there
are also issues that may significantly influence result inter-
pretation (e.g. the variable and rapidly changing test sensi-
tivity, specificity and positive predictive value, and the off-
label use of genetic tests), and may therefore require sig-
nificant educational support as the volume of genetic tests
increases exponentially.
Discussion
Dimensions of genetic test results relevant to EMR
systems
A. Characteristics of the health condition
How to display and protect genetic information in ways
that allow clinicians to use this information to help
patients while also protecting their privacy has been dis-
cussed and debated for years. Some genetic test results
are predictive and confirm a propensity for or certainty
of developing a condition prior to actually developing it
(e.g. Huntington’s disease, various cancers). Some of
these conditions may have screening or preventative
actions that are available to decrease the likelihood of
disease, while others may have only psychological impli-
cations from knowing. Individuals may want personal
control over access to genetic test results because they
are fearful that knowledge of this information will lead to
discrimination, for example in employment or insurance.
They may be reluctant to be tested at all for some condi-
tions, and if tested, reluctant to have results documented
in their medical record. While few instances of pre-symp-
tomatic genetic discrimination have been documented,
the fear of such discrimination led to the federal imple-
mentation of the Genetic Information Nondiscrimination
Act (GINA) of 2008 [5,6] and other state laws that pro-
vide specific genetic privacy protections.
For sensitive conditions such as certain cancers or
dementias, patients may not wish others to know about
their condition or their risk of developing the condition;
these concerns are not different from the issues that arise
with other potentially stigmatizing medical information
(such as sexually transmitted diseases, HIV, mental health
conditions, and learning disabilities). Patient concerns
about being stigmatized based on a genetic test result will
likely vary from person to person and from culture to cul-
ture. When people fear being stigmatized they will want
more complete control over disclosure of genetic tests
results, even to other health care providers, and may want
to be consulted every time this potentially stigmatizing
information is requested.
Balancing the many benefits of making genetic test
results widely accessible in a patient’s medical record are
the potential benefits of restricting access to certain
genetic test results and the need for appropriate and per-
sonalized privacy protection [see also 7-8]. While the issue
of protection of genetic information specifically remains
widely discussed [e.g. 4], recent trends suggest that genetic
information should be accorded the same privacy protec-
tions as other health information rather than requiring
special protections [9,10]. One study suggests that patients
do not generally view genetic information as different
from other types of medical information, but rather they
make distinctions about the sensitivity of the condition
being tested and who should have access to the informa-
tion [11]. This study also suggested that patients feel all
health information should be protected and that personal
control over who accesses information was important. In
an EMR patients could potentially opt for genetic test
results to be safeguarded, for example with special privacy
safeguards including password protected sections or a
“break the glass” mechanism, where an authorized user
could override access restrictions only under emergency
situations [12]. Health IT systems will need to develop
methods to implement these safeguards, and track patient
concerns and preferences to determine when to turn on
these protections.
B. Patient preferences to know or not know genetic test
results
One of the difficulties of designing access controls for
genetic test results is that different patients may react to
the same test result differently, particularly when a genetic
test result for a chronic condition (e.g. diabetes) or preven-
table condition (e.g. lung cancer, skin cancer) is determi-
nistic based on a patient’s genetic makeup [13] and when
inconsistency in health care provider understanding of
these test results may lead to patient confusion. For
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g e n e t i cc o m p o n e n tm a ya c t u a l l yr e m o v es t i g m aa n d
increase the likelihood that the patient and their family are
proactive about managing it. Patients in this example who
are told that their genetic background makes them more
susceptible to diabetes may stop blaming themselves for
the disease. They could adopt the analogy of myopia, and
consider diet and lifestyle changes the same as wearing
glasses: a logical step to address a condition they cannot
change. Dieticians and other providers seeing this infor-
mation in their medical record can be proactive about
helping patients take positive steps to improve their - and
their families’ - overall health. Alternatively, other patients
given the same information could become fatalistic and
believe that no matter what actions they might take they
are certain to develop the disease because they have a
genetic predisposition. Restricting access to the informa-
tion can prevent multiple health care providers from giv-
ing the patient conflicting information about their
likelihood of actually developing the disease and the bene-
fits of preventive action. In addition to reacting to test
results differently, patients may be ambivalent about
knowing genetic information at all. Rarely, patients may
change their minds about knowing all or some of the
results of a genetic test after having the test performed.
An example might be a patient at risk for a late onset neu-
rological disorder such as Huntington’s disease or Amyo-
trophic Lateral Sclerosis (ALS).
More frequently, multiplex tests that assess a broad
range of conditions in a single test can unexpectedly reveal
secondary information. These tests cover more conditions
than necessary to reduce the costs of test development
and implementation while improving diagnostic coverage.
For instance, a chromosome microarray done as a diag-
nostic test in a child with an intellectual disability may
also identify an increased risk of adult-onset cancer when
a relevant gene is identified as deleted. The ease of infor-
mation storage in an EMR may mean that more informa-
tion than is strictly medically necessary may then be
placed in a patient’sr e c o r d .I faw i d er a n g eo fg e n e t i c
information is stored in an EMR, including results from
multiplex tests, some of this information will not be
immediately relevant to the patient’s health care. And as
more and more information from genetic tests is stored in
an EMR, the likelihood increases that a health care system
will access and use this information in ways that improve
patient care but that are unintentionally upsetting to a
patient. For example, a patient could be preemptively
denied access to a medication that is likely to be ineffective
for them based on their genetic makeup rather than pre-
sented with choices and given the opportunity to weigh
the risks and benefits.
There are serious ethical considerations that go along
with inadvertently coming into possession of information
about a patient’s probability of developing a disease or
reacting to a medication if the patient did not agree to
that specific testing. Multiplex tests, such as a genome-
wide single nucleotide variants (SNVs; also known as sin-
gle nucleotide polymorphisms or SNPs) genotyping
assessment or whole genome/exome sequencing, may be
t h eo n l yc h o i c eo rt h eb e s tc h o i c eap r o v i d e rh a sw h e n
ordering a genetic test for a patient. A patient who
underwent genotyping for one reason may also learn, for
example, that she is at high risk of a serious side effect if
given a specific medication that her primary care doctor
would otherwise have prescribed. If the full genotyping
results were stored and updated in an EMR the patient
could be protected from receiving such a medication and
suffering the side effects. There may also be a strong
financial argument if not moral obligation to prevent
patients from receiving expensive and potentially harmful
drugs if it is unlikely the patients would benefit from
them.
An EMR could have safeguards built in to protect
against accidental revelation of unwanted information
from the results of a multiplex test that are stored in the
patient’s medical record. One system that could be consid-
ered to address these ongoing issues would be to use the
EMR or a patient interface that contacted patients on a
regular basis to inquire about their preferences for privacy
and information sharing. While informed consent educa-
tional materials would need to be created to support this,
it would allow us to use technology interfaces to regularly
prompt patients for current preferences and permissions
for use of their genetic information in their health care.
C. Clinician characteristics and training
A genetic test can serve as a clinical diagnosis that allows
for prognostication and as a specific treatment plan. For
example, a woman who carries specific mutations in the
BRCA1 or BRCA2 (BReast CAncer) genes has a much
higher risk for breast and ovarian cancer over her lifetime
than the general population. Medical recommendations
for this patient will likely include more frequent screen-
ings and the consideration of prophylactic removal of the
o v a r i e sb ya g e4 0 ;t h ep a t i e n tw o u l da l s ob ea b l et oc o n -
sider a prophylactic mastectomy [14]. It would be impor-
tant in this case that her gynecologist, oncologist, and
primary care doctor be aware of this test result and its
associated implications. Similarly, a patient with a genetic
mutation in one of the genes responsible for Lynch syn-
drome has a much higher likelihood of developing color-
ectal cancer over his or her lifetime than the general
population. It would be recommended that this patient
have regular colonoscopies at a much earlier age than is
typically recommended [15]. It would be important for
this patient’s primary care doctor, gastroenterologist, and
oncologist to be aware of this genetic test result and diag-
nosis and its implications.
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diagnostic tests that are complex and require specialized
training to interpret, and misinterpretation of test
results can occur in other circumstances, many health
care professionals self-identify as ill-prepared and
under-educated about genetic tests and how to interpret
genetic test results [16,17]. Misinterpretation of any
medical test can have important consequences: uninten-
tional distress, unjustified decisions about future actions,
or unnecessary current actions. Given the difficulty of
interpreting genetic testing results/reports and the
potentially devastating effects of misinterpretation (such
as the decision to terminate a pregnancy or undergo
invasive screening or even prophylactic surgery), it
might be argued that genetic test results should only be
provided to health professionals with specific training in
genetic medicine. Alternatively, interpretation by a cre-
dentialed expert in the field could be a required part of
the reporting of a genetic testing result. When deemed
appropriate, an EMR could restrict access to genetic test
results that have not been interpreted by an expert, or
restrict access to all results (or to other tests that are
complex to interpret) unless specific trainings and com-
petencies have been demonstrated by the accessing
clinician.
Characteristics of genetic test results relevant to access
control and decision support system design
The factors described above that are relevant to how
EMR systems present genetic testing results are arguably
not unique to genetic tests. However, as health care sys-
tems adopt electronic medical records (EMRs) that facili-
tate the storage of extensive genetic data, policies on
access to and use of genetic test results will need to take
the distinctive characteristics of genetic tests into
account. EMRs offer the opportunity to take advantage of
advanced access controls and decision support capabil-
ities. To assess the technosocial needs that arise when
considering how best to use EMRs to control access and
use of genetic test results, we will review the types of
genetic tests that are currently performed and the varia-
tion in their interpretability and complexity. How EMRs
handle different types of genetic information and genetic
test results will likely vary based on these characteristics.
Much of this content draws on information broadly
accepted in the genetics literature. Resources that provide
more in-depth background on genetic conditions and
clinically available testing include: the Gene Tests Web
site http://www.geneclinics.org or http://www.genetests.
org; OMIM: Online Mendelian Inheritance in Man
http://www.ncbi.nlm.nih.gov/omim//; Genetics Home
Reference http://ghr.nlm.nih.gov/; and others described
in Uhlmann and Guttmacher [18].
A. Why all genetic tests are not created equal: Influence of
test purpose on access and decision support needs
Characteristics of different types of genetic tests may
have different implications for how to store the test
results in the medical record and how accessible to make
these results. This section reviews three main types of
g e n e t i ct e s t i n g :( 1 )t e s t i n gt om a k ead i a g n o s i s ,w i t ht h e
goal of improving medical treatment, (2) testing to assist
in reproductive choices, and (3) testing, usually in a pre-
symptomatic manner, to predict future health outcomes.
The reasons a test was ordered and the specific technol-
ogy used in the genetic testing process will also influence
the type of genetic information generated, having down-
stream implications for issues of access and use within an
EMR.
1. Testing to diagnose and improve treatment Some
genetic tests are used to assist with the diagnosis of a med-
ical condition in a patient who is symptomatic, with the
goal of establishing a diagnosis, clarifying prognosis, and
influencing medical management. Often, diagnostic tests
are offered for Mendelian genetic conditions with child-
hood onset, and as such usually entail molecular testing of
a single gene or a panel of genes that are associated with a
small set of related conditions, or in some cases a molecu-
lar cytogenetic test (e.g. comparative genomic hybridiza-
tion, CGH). These conditions make up the majority of the
genetic tests that are currently available, and it is impor-
tant to note that genetic diagnoses can often be made
from clinical features (particularly when no genetic test is
currently clinically available), biochemical measurements,
or DNA based genetic testing. Genetic tests can also be
ordered to rule out a potential genetic condition; if the
test result is negative this reduces the chances that the
patient will have specific symptoms, provides additional
information for treatment plans, and has implications for
the patient’sf a m i l y .
When contemplating access issues for diagnostic genetic
tests, it is generally agreed that widespread access to most
genetic test results in this category is valuable. First, the
genetic test will likely rule in or out a specific differential
diagnosis, which has important implications for coordinat-
ing care across the medical team. Second, when a condi-
tion is genetic, there is an increased likelihood that other
family members are affected or are at risk for having
affected offspring. When seeing a healthcare provider,
medical records to document the condition and specific
diagnosis are certainly helpful, but the information about a
relative’s genetic test results is especially critical in order-
ing the appropriate test (usually a single-site mutation ana-
lysis) and for more clear-cut interpretation of results for
these relatives. For example, if a family member is known
to have a specific mutation that is not on most standard
testing panels this information will allow a healthcare
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relative and avoid a false negative result. Having these
genetic test results available can cut costs for other family
members and potentially for insurance providers and the
medical center, as testing can be mutation-specific versus
a more general testing approach (e.g. sequencing an entire
gene or genes). Results may also be available more rapidly.
Clear documentation of the specific gene and mutation
site in medical records and family letters can allow rela-
tives and their health care professionals to obtain proper
testing and maximize test sensitivity and specificity. As
such, if the result is provided in a protected part of the
medical record or is not easily accessible it may be more
difficult for clinicians to identify the relevant information.
Beyond specific diagnostic genetic testing, pharmacoge-
netic testing increasingly can be done to choose a medica-
tion that will perform differently in patients with
different genetic markers; medical recommendations may
be based on pharmacogenetic test results with the hopes
of directly improving patient care. For example, genetic
variants alter the metabolism of warfarin, and although
the evidence base remains under development, testing
can improve dosing and make use of the medication
safer [19]. Prescribing recommendations, including FDA
labeling in some cases [20], are currently available based
on pharmacogenomic results including warfarin (for the
biomarkers CYP2D9 and VKORC1) and some cancer
treatments that are prescribed to individuals on the basis
of specific genetic test findings (e.g. Tamoxifen based on
Estrogen receptor biomarker results and trastuzumab
based on Her2/neu biomarker results). The patient’s
genetic information is of high relevance to providers
when prescribing or reviewing these medications. Having
the results of pharmacogenetic tests available in the med-
ical record to all providers, ideally along with “point of
care reminders” to offer specific genetic tests before a
medication is prescribed and/or regarding appropriate
management on the basis of the results, can prevent the
patient from receiving ineffective or even harmful medi-
cations [21].
In sum, the characteristics of the health conditions that
can be tested for with this type of genetic test (they have
clear implications for diagnosing and guiding treatment)
should likely be the key determining factor for setting
access controls on the results. Access controls should be
minimized for this type of test, but ideally display of test
results should be paired with decision support regarding
interpretation of the findings and implications for clinical
decisions. Access to genetic information relevant to medi-
cation response could still be restricted to clinicians such
as clinical pharmacists or available with pharmacy decision
support systems rather than automatically to all clinicians.
2. Testing to assist in reproductive choice Three types
of genetic tests assist with reproductive choices: carrier
screening testing, pre-implantation genetic testing, and
prenatal testing. One thing that these tests have in com-
mon is that they do not have direct health implications
for the patient, but rather may impact the health of
their future children or the health of other relatives.
The key determining factor for setting access controls to
this type of test should therefore be patient preferences,
with default access controls in an EMR more narrowly
restricted to reproductive health specialists (e.g. obstetri-
cians) and geneticists.
Genetic carrier screening is typically offered when a
person is of child-bearing age to predict risks for autoso-
mal recessive (or X-linked) conditions for their offspring.
Carrier screening may be population-wide, on the basis
of ethnicity, or done on the basis of family history. This
type of genetic testing is not medically necessary for the
patient, as its primary use is to provide information rele-
vant for reproductive choice and informed decision mak-
ing. Examples of conditions for which carrier screening is
typically done on a population basis and/or offered on
the basis of ethnicity include cystic fibrosis and spinal
muscular atrophy for women of all ethnic backgrounds;
Tay Sachs, Canavan disease and Niemann-Pick disease
testing for those of Ashkenazi Jewish heritage; and hemo-
globinopathies, such as sickle cell disease, for those with
African American backgrounds.
Preimplantation genetic diagnosis or screening may be
offered for several reasons: as part of in vitro fertilization,
when a couple has had difficulty conceiving or maintaining
ap r e g n a n c y ,o ra sam e a n so f“preconception diagnosis”
for an inherited condition for which the potential fetus is
at risk. It may also be used for selecting human leukocyte
antigen matched children who may be future donors for
other offspring who are affected by a serious condition, for
gender selection for medical conditions (e.g. an × linked
condition carried by the mother), or other personal and
potentially controversial reasons.
Prenatal genetic screening or diagnostic testing is
offered to all pregnant women in the United States to
help detect certain conditions during the pregnancy.
These genetic tests may be done through analysis of
maternal serum analytes (augmented in some cases by
ultrasound screening) or by diagnostic genetic analysis of
fetal DNA obtained through chorionic villus sampling or
amniocentesis. In the near future, it may also become
possible to broadly offer noninvasive diagnostic cell free
fetal DNA testing through maternal serum [22]. Test
results allow the couple to decide whether to continue a
pregnancy, or allow the couple to prepare for delivery
and childcare or adoption of an affected child.
A major characteristic of genetic testing results for
reproductive purposes is that the individual about whom
the information reveals personal (and in many cases pre-
dictive) genetic health information is not the patient, but
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setting access controls on test results because it raises the
question of where the information should be stored.
While results may have relevance to the specific preg-
nancy (or future pregnancies, in the case of accurate
recurrence risk counseling), it will not impact the health
of the patient in all but rare cases, and misinterpretation
of carrier status may result in inappropriate medical care
and/or discrimination as was seen, for example, with
sickle cell carriers in the 1970s. Several options could be
considered to encourage appropriate use of this informa-
tion in EMRs, including having reproductive genetic test
results accessible only to certain care providers (e.g.
obstetricians or with patient permission to release, for
example, to family members) and automating transfer of
relevant records (such as positive test results) to the
record of offspring to whom they apply so that key infor-
mation is then available to care for the individual in the
future.
3. Predictive genetic testing Predictive genetic testing
may be done for late-onset conditions for which a patient
is not yet symptomatic. These tests can help the patient
prepare for managing their medical care and allow him or
her to make informed life decisions. Examples of condi-
tions for which predictive testing may be done are Hun-
tington’s disease and certain other neurodegenerative
diseases (e.g. dementias), as well as Breast and Ovarian
Cancer syndrome and certain other cancer syndromes in
which a higher risk can be predicted based on genetic test
results. Many of these conditions can be caused by muta-
tions inherited from a single parent, cause a high risk
(60-100%) of developing the condition (i.e. are high pene-
trance), and are believed to occur primarily in people with
a family history of the condition. But there is increasing
variability in this area as genome-wide single nucleotide
polymorphism (SNP) genotyping and sequencing technol-
ogies improve for more common conditions involving
multiple genes (e.g. diabetes, heart disease, and cancers).
These conditions are less likely to appear inherited by
patients, in part because they are more common in the
population and because the various at-risk genotypes con-
vey a far lower risk of developing the condition.
There are two critical issues that impact policies on
access to predictive genetic information. The first is that
the individual does not yet (and may or may not ever) have
the specific condition for which testing is being performed.
This opens up the potential for genetic discrimination on
the basis of awareness of these test results, and this type of
testing is the one for which privacy issues are most salient.
In the past some patients have even considered anonymous
testing or avoided testing at all to minimize such risks.
Again, the current GINA legislation and supplemental
state laws provide various levels of protection against
health insurance and employment discrimination, but
there are still concerns that suggest that some level of
protected access would be most appropriate, either by
patient consent or to specific health care providers depend-
ing on the exact genetic test result. The second issue that
arises with predictive genetic test results is difficulty with
interpretation. Clinician training is therefore critical for set-
ting policies on access to this type of genetic test results.
Many healthcare workers are unfamiliar with the concept
of decreased penetrance, and may inappropriately tell
patients that these test results are fully predictive. Decision
support tools that educate about the role of the environ-
ment (where appropriate) and early screening may help
improve patient education and outcomes.
B. Interpreting genetic test results and the need for
educational prompts in the EMR
Regardless of the reason for ordering a genetic test, the
test result itself can give the health care provider different
types of information and have varying levels of interpret-
ability. While analytic validity is usually high, there is
much less consistency in the degree of clinical validity and
clinical utility of genetic testing at this time (the clinical
impact of a genetic mutation and whether there are clini-
cal interventions to be made based on the result) [23].
Additionally, genetic test development is not yet regulated
by the Clinical Laboratory Improvement Amendments
(CLIA) oversight process. There is tremendous variability
in the degree of information and interpretation of results
returned by different laboratories, making it challenging
for a non-genetics specialist to interpret genetic test
results accurately [24,25]. These issues can create signifi-
cant ambiguity about result interpretation, and decisions
regarding medical record access to these results should
consider the clinical utility of the findings and the avail-
ability of clinical decision support systems to guide health-
care provider use of test findings. Results without clear
clinical utility should either be restricted to genetic specia-
lists for interpretation, or at a minimum not be promi-
nently displayed in EMR interfaces.
1. Simple, certain test results An example of a straight-
forward result to interpret would be from a genetic test
for a Mendelian disorder for which (a) there is a single
gene locus affected, and/or a single mutation that occurs
for the condition, and (b) high likelihood the disorder
will express itself when the mutation is present. These
test results would show that the mutation is either pre-
sent or not, and give the patient a very clear result with a
clear outcome. Few genetic tests fit neatly into this cate-
gory. One example is Huntington’s disease (HD), which
is caused by a genetic mutation where a specific trinu-
cleotide sequence is repeated a variable number of times,
and persons with a number of these repeated trinucleo-
tides over a certain threshold will develop HD. A result
from a test for HD would typically provide the number
of expanded repeats as well as the normal and abnormal
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one allele) means that the patient does have HD or will
develop it if they live long enough, and a negative result
(both alleles less than 30) means that the patient does
not and will not have HD. Despite this apparently clear
test result, there remains variability in the age of onset
and the progression of symptoms that cannot be defini-
tively predicted on the basis of the genetic test, and there
are other diseases which mimic the symptoms of HD.
Another relatively straightforward test result would be a
prenatal chromosome analysis from an amniocentesis,
called a karyotype, in which all of the cells analyzed had
the same unambiguous chromosome count with no extra
or missing pieces of chromosomes and no chromosome
inversions or translocations. The certainty of the test
result, such as a positive result for Down syndrome in
which an extra chromosome 21 is seen, would be very
high (over 99.8%). Depending on the lab, however, the
report with this karyotype result may or may not state the
reason for the test (e.g. elevated risk for Down syndrome),
interpret the results as normal or otherwise, include an
image of the chromosomes, or state the gender. Given the
certainty of this type of test results, providing broad clini-
cal access to findings in combination with clear decision
support and/or provider education is encouraged.
2. Complex test results: analytically valid results with
clinical uncertainty A genetic test may have very certain
results and high analytic validity but the result may not be
simple to interpret and therefore have unclear clinical
validity or utility that will likely change over time as tech-
nologies and our clinical knowledge improve. When test
results have unclear clinical validity or utility it may be
appropriate for access to the results to be automatically
restricted to genetic specialists unless there is additional
intervention. Moreover, decision support prompts should
be added to the EMR to provide educational information
about the clinical uncertainty that is present, and suggest
additional consultations with experts. For example, one
possible result of a karyotype or molecular cytogenetic
analysis (a test which looks for specific genetic sequences
on chromosomes) is that the same genetic complement is
seen in every cell tested, but the complement contains
complicated duplications and deletions of parts of chro-
mosomes (copy number variants or CNVs) rather than the
normal amount of genetic information. While it is highly
certain that this result is accurate, it is complicated to
interpret and the formulation of a prognosis may be diffi-
cult. A clinician interpreting a test result that identifies
CNVs must review the literature for case reports and addi-
tional information about the specific duplications or dele-
tions, assessing potentially affected genes and their
functions. All or part of this information may not be read-
ily available, it may change over time, and a lab may not
report all of this information along with the results.
Additional testing is often required to further clarify the
interpretation (e.g. on parents, to determine if the CNV
was inherited or de novo).
Testing complexity also arises when a gene has many
potentially detectable mutations (high allelic heterogene-
ity) and various testing approaches can be taken, influen-
cing the potential sensitivity of the test performed. An
important though not unique example of this situation is
Cystic Fibrosis (CF) screening [26]. CF is caused by
mutations in a single gene (CFTR); however more than
1500 different changes in this one gene can cause CF.
B e c a u s eap a t i e n tm u s tc a r r yam u t a t i o no nb o t hc o p i e s
of their CFTR gene to have CF they frequently have two
different mutations (compound heterozygosity), making
prognostication difficult since genotype-phenotype corre-
lations are limited. Modifier genes, most of which are
unknown at this time, can result in patients with the
same combination of mutations showing different symp-
toms, even within the same family, making it even more
difficult to prognosticate.
There are also several CF testing methods available
[26]: targeted mutation panels which test for a limited
number of the more common mutations and full gene
sequencing which would detect a higher percentage of
mutations across the gene but may not detect large dupli-
cations or deletions or some types of peripheral muta-
tions. The testing method affects the test sensitivity,
making the results more or less certain as well as more
challenging to accurately interpret. A typical CF panel
test report contains a list in genetic notation of all of the
mutations that were tested for and whether any were
found. The interpretation of the report is typically left to
the provider who receives the report from the lab.
Because the test sensitivity is not 100%, a negative result
(e.g. a result where an asymptomatic person is found to
carry no identifiable mutation) means that there are no
mutations which could be found by the selected test
panel, but it does not mean there are no mutations pre-
sent. There is always some residual risk that a disease-
causing mutation was not detected by the test, in part
because the test panel does not cover all possible muta-
tions. Misinterpretation of a critical point like this could
lead a patient to falsely believe that they are not at risk of
having an affected child and potentially create malprac-
tice issues. Additionally, testing panels can change over
time making it complicated to know if and when
previously negative testing should be repeated. Point of
service reminders, educational prompts, and recommen-
dations to consult specialists would all be useful decision
support tools within an EMR to help providers maintain
awareness of the changing pace of genetic technologies.
Finally, tests for single nucleotide variants (SNVs) are
the types of tests most commonly done by direct-to-
consumer genetic testing companies and during research
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for certain diseases or conditions. Testing methods for
SNVs have high analytic validity and can reliably detect
whether a SNV that was found to be associated with
disease risk is present or not. However, the clinical
validity of such testing, in other words the association
between a certain SNV and having a higher risk for a
certain disease, is usually fairly weak. This leaves the
provider with significant uncertainty about the implica-
tions for the patient. For example, not all persons with a
specific SNV will develop colorectal cancer, and persons
without the variant may develop the cancer anyway. In
addition, some conditions may have many SNVs asso-
ciated with them, and there are not yet robust methods
for combining and weighing the risks across an array of
SNVs. Finally, several studies have shown significant
variation in the interpretation of absolute risk assigned
by the various testing companies even on the basis of
the same genotype information [27,28], and the ultimate
clinical interpretation can vary as new SNVs are uncov-
ered or as their usage varies across companies [29].
Given the generally weak clinical validity of these
genetic test results, a policy that defaults to restricting
access to them to genetic specialists may prevent unwar-
ranted clinical concern or misguided treatments based
on misunderstanding the results. As methods for better
estimating risk are generated, decision support systems
will be required to effectively use these algorithms.
Summary
Electronic medical records enhance both the ability of a
health care system to store complex, lengthy genetic test
result data in a patient’s record and the ability of the sys-
tem to control access to that informa-tion. Test results
placed in an EMR can be more easily accessed by a wider
range of providers who do not have to request and wait
for a paper chart, and also offer an opportunity to build in
privacy safeguards which cannot be built into a paper
chart. For example, EMRs often allow access to psychiatric
records to be more restricted than access to cholesterol
test results, and they can allow prenatal providers to flag a
record when a patient does not wish (for example) to
know the gender of her fetus. Similarly, a health care sys-
tem could place additional privacy restrictions around
genetic information pertaining to sensitive conditions,
such as adult onset disorders like Huntington’s disease or
cancer susceptibility genes. The type and extent of protec-
tion, if any, is currently left up to the institution or depart-
ment to decide upon and implement, therefore there is
little consistency between institutions in the use of these
privacy safeguards in EMRs [3]. (This extra privacy is typi-
cally created because of the sensitivity of the information
not because it is genetic in nature).
Genetic testing can provide clear benefits to patients and
providers in terms of improving diagnosis, prognostica-
tion, and treatment planning. However, these tests also
pose risks to patients of stigma-tization, distress, and dis-
satisfaction, and risks to providers of misinterpretation
and subsequent errors in treatment recommendations.
There are also inevitable risks of miscommunication
between patients and providers and between different pro-
viders with access to test results. EMRs have the potential
to provide clinicians with better access to genetic test
results, but without specific forethought in the design of
these systems this may not necessarily lead to better inter-
pretation or clinical care. Health care systems must care-
fully consider when access to genetic test results and
decision support for their interpretation is safe and desir-
able and how to implement systems to prevent sharing
and access when the risks are unacceptable. We believe
there are three key dimensions to these access decisions:
(1) the specific characteristics of the test and the resulting
raw data, including sensitivity, interpretability, possible
secondary findings, and the likely sensitivity of results for
patients, (2) patient preferences for access and use of
genetic information in their health care, and (3) level of
clinician training in genomic medicine, test interpretation,
and patient counseling. Decisions about the extent of clini-
cian access to test results should vary based on these three
factors in ways we have suggested above.
Genetic tests have widely varying implications for
patients’ immediate and future health care decisions, as
well as for their family members. For optimal use and
patient acceptance of genetic testing as part of medical
care, systems and policies should ensure appropriate use
of and access to genetic information [30]. There is no a
priori reason for EMRs to treat all genetic test results the
same, with uniform policies on restricting or allowing
access. We recommend implementing some level of
access control on sensitive genetic (and other) data, spe-
cifically controls around data access for non-specialist
providers and controls that consider patients’ input into
allowed uses of genetic test results they consider sensi-
tive. Providers trained in genetics, including clinical
geneticists and genetic counselors, should be involved in
the specification of these record systems as they are best
trained to interpret and understand the proper use of
results from the diverse types of genetic tests and predict
the impacts of testing and results on patients with diverse
conditions. We encourage EMR developers to consider
building in point-of-care reminders or decision support
tools [31] around genetic data and screening recommen-
dations to support health care providers in remaining up-
to-date in the implications of genetic test results for
medical management. Finally, we also strongly urge
health care systems to be cautious managing multiplex
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single specific purpose, as the patient may not have con-
sented to or considered the implications of all the test
results.
Health IT systems have the potential to greatly facili-
tate using genetic information to both improve health
outcomes and respect the individual preferences of
patients regarding their care. To facilitate this work we
suggest that any panels creating clinical guidelines for the
use of genetic test results in clinical care include decision
support and health information technology experts to
ensure recommendations can be translated into tools
that adequately guide practice. As more and more health
care systems implement genetic testing in the context of
comprehensive electronic medical records, balancing
clinical possibilities and patient preferences will be a sig-
nificant challenge to their successful implementation and
crucial to patient acceptance and clinical adoption of the
potential treatment advances from genomic medicine.
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